EXEL heads into its May 5 Q1 results with short sellers at their most aggressive in months — and the stock down 4.6% on the week despite an otherwise healthy April.
The short interest story is the week's defining feature. At roughly 13.9% of the free float, EXEL's short position is substantial and still climbing. Shorts have grown steadily since early April, adding roughly 8% in share terms from late March to now. The one-month increase of 9.2% is not a rounding error — it represents a deliberate rebuild heading into the earnings print. Days to cover runs at 6.5 days, meaning a rapid exit would take meaningful time, adding an element of structural pressure on the bear side.
The lending market tells a contrasting story, however. Borrow availability is not tight — cost to borrow is running at just 0.50%, near the low end of this year's range. Availability remains loose, suggesting that building a short position is still easy. That matters: a low-cost, freely available borrow means shorts are not yet crowded out and there is no obvious squeeze catalyst from the lending side. The ORTEX short score of 62.6 is elevated but has been largely range-bound between 62 and 63.5 for the past two weeks. Options positioning is similarly measured — the put/call ratio of 0.73 is almost exactly in line with its 20-day average, carrying a z-score of just 0.17. Neither options traders nor the borrow market are signalling imminent alarm; the short-side pressure is being built methodically rather than anxiously.
The Street is caught in the middle. Consensus sits at Hold, with nine Hold ratings against a mean price target of $47.53 — roughly 6% above the current $44.69 close. The most recent action, from Barclays in late April, was a modest target raise from $44 to $45 while keeping an Equal-Weight rating — a classic "acknowledge the momentum but stay cautious" move. RBC cut its target from $46 to $43 in March, signalling some concern about the medium-term growth outlook. HC Wainwright remains the notable outlier with a Buy and a $54 target. The bull case centres on Cabometyx franchise momentum and a strong balance sheet carrying roughly $1.6 billion in cash. The bear case focuses on the limits of that franchise: Cabometyx exclusivity comes under pressure beyond FY26, and the commercial future of the broader pipeline — including zanzalintinib — remains unproven. Valuation is not obviously stretched: the P/E of 12.5x and EV/EBITDA near 9x are modest for a profitable biotech with positive EPS momentum, ranking in the 72nd percentile on the EV/EBIT factor score. The RSI of 53 is neutral.
Institutional positioning has been broadly stable. BlackRock lifted its stake by around 835,000 shares to 11.9% as of end-March. Vanguard is effectively flat. AQR added over 4.3 million shares as of December — a meaningful quantitative accumulation, though that data is now several months old. The insider picture, by contrast, is one-sided: in mid-to-late February, the CFO, Chief Scientific Officer, an EVP, and multiple directors all sold shares at $43–$45 — the exact range where the stock trades today. The net 90-day insider figure is a net sell of over $57 million. Significance scores are low (2 out of 10 across the board), pointing to routine plan sales rather than distress-driven disposal, but the direction is worth noting.
The next catalyst is clear: Q1 results on May 5. The two most recent earnings reactions were modest — both produced a small first-day loss followed by a slight recovery over the following five sessions. The stock fell less than 1% the day after February's print, then added 3.5% over the week. That pattern suggests the market has not been punishing near-term results aggressively, but a 9% single-month rebuild in short interest heading into this quarter's report implies the bears have different expectations this time. The key questions are whether Cabometyx revenue growth holds up against a demanding comparison period, and whether the company offers any update on the zanzalintinib development timeline that could shift sentiment on the pipeline beyond FY26.
See the live data behind this article on ORTEX.
Open EXEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
